BIOC - Biocept, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0401
-0.0299 (-2.7944%)
As of 3:43PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.0700
Open1.0500
Bid1.0400 x 2000
Ask1.0500 x 2800
Day's Range1.0400 - 1.0800
52 Week Range0.7400 - 3.3900
Volume174,271
Avg. Volume293,453
Market Cap31.47M
Beta2.90
PE Ratio (TTM)-0.98
EPS (TTM)-1.06
Earnings DateNov 7, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube5 hours ago

    ETFs with exposure to Biocept, Inc. : October 23, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biocept, Inc. Here are 5 ETFs with the largest exposure to BIOC-US. Comparing the performance and risk of Biocept, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Biocept Launches Pathology Partnership Initiative Expanding Access of Proprietary Liquid Biopsy Testing to Community Pathologists and Hospitals
    PR Newswire5 days ago

    Biocept Launches Pathology Partnership Initiative Expanding Access of Proprietary Liquid Biopsy Testing to Community Pathologists and Hospitals

    SAN DIEGO, Oct. 18, 2017 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid testing designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces the launch of its molecular pathology partnership initiative, the aim of which is to incorporate community pathologists into the review of biomarkers found in liquid biopsy for patients diagnosed with cancer. Patient specimens will continue to be sent to Biocept for processing in its CLIA-certified, CAP-accredited laboratory. "Having pathologists involved in the interpretation of liquid biopsy is important, as community physicians and hospitals want to take advantage of leading-edge medical solutions by providing the best patient care in their local health system," said Michael Terry, Senior Vice President, Commercial Operations at Biocept.

  • Renowned Lung Cancer Expert Fred R. Hirsch, M.D., Ph.D. Joins Biocept's Clinical Advisory Board
    PR Newswire12 days ago

    Renowned Lung Cancer Expert Fred R. Hirsch, M.D., Ph.D. Joins Biocept's Clinical Advisory Board

    SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that Fred R. Hirsch, M.D., Ph.D. has joined its Clinical Advisory Board.  Dr. Hirsch is Professor of Medicine and Pathology at the University of Colorado Cancer Center. "We welcome Dr. Hirsch to our Clinical Advisory Board and look forward to benefitting from his significant expertise in lung cancer," said Biocept's President and Chief Executive Officer Michael Nall.  "Dr. Hirsch is a prominent figure in the clinical and academic communities focused on lung cancer, and has received numerous awards and authored hundreds of peer-reviewed papers.  He is involved in studies of lung cancer diagnosis, staging, prevention, early detection and treatment that have favorably impacted the care of lung cancer patients, and his research has helped to identify and validate predictive markers for personalized lung cancer therapies.

  • Capital Cube13 days ago

    ETFs with exposure to Biocept, Inc. : October 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biocept, Inc. Here are 5 ETFs with the largest exposure to BIOC-US. Comparing the performance and risk of Biocept, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • What You Must Know About Biocept Inc’s (BIOC) Risks
    Simply Wall St.19 days ago

    What You Must Know About Biocept Inc’s (BIOC) Risks

    If you are a shareholder in Biocept Inc’s (NASDAQ:BIOC), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...

  • Biocept, Inc. :BIOC-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
    Capital Cube19 days ago

    Biocept, Inc. :BIOC-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017

    Categories: Yahoo FinanceGet free summary analysis Biocept, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 1.28 million, Net Earnings of USD -5.69 million. Gross margins widened from -151.87% to -85.21% compared to the same period last year, operating (EBITDA) margins now -419.62% from -671.60%. Change in operating cash ... Read more (Read more...)

  • Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States
    PR Newswire20 days ago

    Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

    SAN DIEGO, Oct. 3, 2017 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered into a Promotion and Marketing Agreement with Miraca Life Sciences, Inc. (MLS) to market Biocept's Target Selector™ liquid biopsy tests and services to community-based oncologists and hematologists in specified sales territories in the United States. Based on the Agreement, MLS' sales professionals will promote Biocept's Target Selector testing to both their existing and new clinician clients in the specified sales territories.

  • 5 Medtech Stocks to Steer Clear of Amid Political Chaos
    Zackslast month

    5 Medtech Stocks to Steer Clear of Amid Political Chaos

    In view of the current political scenario and unfavorable metrics, these five MedTech stocks are best avoided for now.

  • Biocept Launches Liquid Biopsy Test for NRAS Mutations
    PR Newswire2 months ago

    Biocept Launches Liquid Biopsy Test for NRAS Mutations

    SAN DIEGO, Sept. 5, 2017 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces the commercial availability of its assay for mutations of the NRAS oncogene. The assay can be used to detect and monitor an actionable biomarker associated with multiple cancer types such as metastatic melanoma, colorectal and lung cancer.

  • Biocept to Present at the 6th Annual Gateway Conference on September 6, 2017 in San Francisco
    PR Newswire2 months ago

    Biocept to Present at the 6th Annual Gateway Conference on September 6, 2017 in San Francisco

    SAN DIEGO , Aug. 28, 2017 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve ...

  • Biocept and UT Southwestern Medical Center Announce Clinical Study to Profile and Monitor Non-Small Cell Lung Cancer Patients with ALK Rearrangements
    PR Newswire2 months ago

    Biocept and UT Southwestern Medical Center Announce Clinical Study to Profile and Monitor Non-Small Cell Lung Cancer Patients with ALK Rearrangements

    SAN DIEGO, Aug. 17, 2017 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces it has entered into a clinical study agreement with the University of Texas Southwestern Medical Center (UT Southwestern Medical Center). Led by recognized oncologist and ALK mutation researcher Dr. Saad Khan, the study is designed to evaluate the clinical utility of Biocept's Target Selector™ platform for patients diagnosed with ALK-positive non-small cell lung cancer and treated with ALK-inhibitor therapy.

  • Biocept Enters Into Exclusive Distribution Agreement with Global Laboratory Product Supplier VWR
    PR Newswire2 months ago

    Biocept Enters Into Exclusive Distribution Agreement with Global Laboratory Product Supplier VWR

    Patented blood collection tubes developed by Biocept validated to preserve ctDNA for up to 96 hours at room temperature allowing for intact shipping of liquid biopsy samples from regions around the world ...

  • Biocept Reports Second Quarter 2017 Financial Results
    PR Newswire2 months ago

    Biocept Reports Second Quarter 2017 Financial Results

    - Reported revenues of $1.3 million in 2Q 2017 vs. $663,000 in 2Q 2016, up 93%, or 64% excluding the impact of conversion to accrual-based revenue recognition - Launch of "AND" campaign supports ...

  • ACCESSWIRE2 months ago

    Investor Network: Biocept, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 10, 2017 / Biocept, Inc. (NASDAQ: BIOC ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 10, 2017 at 4:30 PM Eastern ...

  • Biocept Announces Private Placement of $2.2 Million of Common Stock with Ally Bridge LB Healthcare Master Fund
    PR Newswire2 months ago

    Biocept Announces Private Placement of $2.2 Million of Common Stock with Ally Bridge LB Healthcare Master Fund

    SAN DIEGO, Aug. 10, 2017 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered into a Common Stock and Warrant Purchase Agreement with Ally Bridge LB Healthcare Master Fund Limited for the private placement of 1,466,667 shares of its common stock and warrants to purchase up to an aggregate of 1,434,639 shares of its common stock at a combined offering price of $1.50. The warrants, which will have a per share exercise price of $1.50, are exercisable immediately and will expire five years from the date of issuance.

  • Biocept Executes Preferred Provider Agreement with Scripps Health Plan Expanding Patient Coverage for its Liquid Biopsy Platform
    PR Newswire3 months ago

    Biocept Executes Preferred Provider Agreement with Scripps Health Plan Expanding Patient Coverage for its Liquid Biopsy Platform

    SAN DIEGO, Aug. 7, 2017 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered into a preferred provider agreement with Scripps Health Plan. Scripps integrates its award-winning providers and facilities with a robust health plan, enabling large businesses to offer employees access to comprehensive care through a single source. With this and other health plan agreements, over 190 million covered lives have in-network access to Biocept's liquid biopsy platform.

  • Capital Cube3 months ago

    ETFs with exposure to Biocept, Inc. : August 3, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biocept, Inc. Here are 5 ETFs with the largest exposure to BIOC-US. Comparing the performance and risk of Biocept, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Biocept to Release Second Quarter 2017 Financial Results and Host Investor Conference Call on August 10, 2017
    PR Newswire3 months ago

    Biocept to Release Second Quarter 2017 Financial Results and Host Investor Conference Call on August 10, 2017

    SAN DIEGO , Aug. 3, 2017 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve ...

  • Global stocks rise on corporate earnings, ahead of Fed
    Associated Press3 months ago

    Global stocks rise on corporate earnings, ahead of Fed

    World stock markets rose Wednesday, lifted by generally positive corporate earnings and as investors kept a cautious eye on the Fed's upcoming interest rate decision. KEEPING SCORE: In Europe, France's ...

  • Associated Press3 months ago

    Drugmaker GSK reviewing its R&D programs under new CEO

    LONDON (AP) — Drugmaker GlaxoSmithKline says it will halt some 30 clinical and pre-clinical programs as it reviews its research and development pipeline and focuses on improving efficiency.

  • Accesswire3 months ago

    Featured Company News - Biocept Commercially Launches Progesterone Receptor Liquid Biopsy Test

    LONDON, UK / ACCESSWIRE / July 17, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Biocept, Inc. (NASDAQ: BIOC ), following which we have published ...

  • Biocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy Test for Progesterone Receptor Detection
    PR Newswire3 months ago

    Biocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy Test for Progesterone Receptor Detection

    Biocept now offers 14 clinically actionable biomarker tests, including all validated biomarkers for breast cancer in NCCN Guidelines® SAN DIEGO , July 14, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), ...

  • Novel leukemia treatment could be 1st US gene therapy
    Associated Press3 months ago

    Novel leukemia treatment could be 1st US gene therapy

    A treatment for a common childhood blood cancer could become the first gene therapy available in the U.S.

  • Capital Cube3 months ago

    ETFs with exposure to Biocept, Inc. : July 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biocept, Inc. Here are 5 ETFs with the largest exposure to BIOC-US. Comparing the performance and risk of Biocept, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube4 months ago

    ETFs with exposure to Biocept, Inc. : June 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biocept, Inc. Here are 5 ETFs with the largest exposure to BIOC-US. Comparing the performance and risk of Biocept, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)